On November 4, 2025 Dispatch Bio, a biotechnology company developing a universal treatment for solid tumors, reported preclinical data supporting its first therapeutic program planned to enter the clinic, DISP-10, and its first-in-class Flare platform, at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 2025 Annual Meeting.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Immunotherapies have had limited success in solid tumors due to the lack of tumor-specific targets and a profoundly immunosuppressive microenvironment. Dispatch’s Flare platform addresses these barriers by systemically delivering a tumor-specific virus that paints a universal synthetic antigen (Flare) on tumor cells, enabling precise recognition by T cells, while reshaping the tumor microenvironment to support immune activity. Data presented at SITC (Free SITC Whitepaper) (Abstract 394) demonstrate strong and consistent tumor labeling, iterative viral amplification and tumor cell clearance across multiple epithelial tumor models.

"These data show that delivering engineered targets specifically to tumor cells allows us to control antigen specificity, while also reprogramming the tumor microenvironment," said Lex Johnson, Ph.D., Co-Founder and Chief Platform Officer. "We are excited to start with CAR T as our first program, and because the Flare approach is modular and not restricted to CAR T cells, it can be extended across multiple immunotherapy modalities."

The company also presented preclinical findings from DISP-10, its first therapeutic candidate (Abstract 393). DISP-10 pairs DV-10, a tumor-targeted virus expressing a modified BCMA antigen (dBCMA) and the immune-stimulatory cytokine IL-18 and chemokine CXCL9, with a clinically validated BCMA-directed CAR T. The viral component installs the target and drives local immune activation, enabling robust CAR T function in solid tumors. DISP-10 demonstrated potent anti-tumor responses in numerous in vitro and in vivo models, with no activity observed in healthy cells. Dispatch plans to initiate a first-in-human Phase 1 study in 2026 to evaluate DISP-10 across multiple solid tumor types.

"DISP-10 creates the right biological context for CAR T cells to function in solid tumors," said Barbra Sasu, Ph.D., Chief Scientific Officer. "The consistency of activity seen with various BCMA-targeted therapies across tumor models gives us confidence in its clinical potential."

(Press release, Dispatch Bio, NOV 4, 2025, View Source [SID1234659405])

On November 4, 2025 MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, reported a financial update and announced its cash position as of September 30, 2025.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"MaaT Pharma is actively executing its financing strategy, building on the momentum of our outstanding Phase 3 results with Xervyteg in acute Graft-versus Host disease patients. With funding secured through February 2026, we are leveraging a balanced mix of dilutive and non-dilutive sources to support our development programs and preserve shareholder value. The recent partnership with Clinigen and the loan agreement with the European Investment Bank are key milestones in this strategy, providing capital-efficient solutions we intend to build upon to sustain our growth throughout 2026," said Eric Soyer, Chief Financial Officer of MaaT Pharma.

Corporate and Financing Update

In July 2025, the Company announced that it has secured a €37.5 million, 4-tranche loan financing from the European Investment Bank (EIB). The financing will support the advancement of its late-stage hemato-oncology clinical programs including the lead-asset Xervyteg, currently under regulatory review by the European Medicines Agency (EMA) for the treatment of acute Graft-versus-Host disease (aGvHD), and the second drug candidate, MaaT033, currently being evaluated in a Phase 2b randomized controlled trial in improving survival for patients receiving allo-HSCT.
The Company announces the successful drawdown in October 2025 of Tranche A for an amount of €3.5 million, together with the issuance, in accordance with the terms of the 24th resolution of the shareholders’ meeting held on June 20, 2025 and Articles L. 228-91 and seq. of the French Commercial Code, of 468,772 warrants to the EIB with an exercise price of 4.5898€, as per the Loan and Warrant agreements with the EIB. The Tranche A loan is payable over two years after a grace period of 4 years, and bears an interest rate of 7% per annum.
In July 2025, the Company announced the signature of an exclusive license and distribution agreement with Clinigen, the global pathfinder accelerating access to critical medicines and a leading European player in hospital distribution and market access, to support market access to Xervyteg for 3rd-line aGvHD patients across Europe, should the submission for Marketing Authorisation be successful. With this partnership, MaaT Pharma demonstrates its capability to supply products to pharmaceutical companies, including those specializing in rare diseases while ensuring commercial scale-up.
The Company received an upfront payment of €10.5 million in July 2025 and may receive up to an additional €18 million, including €12 million upon Marketing Authorization approval and €6 million in commercial milestones. The Company is also eligible for royalty payments on net sales, with a rate in the mid-thirties, as well as recurring cash flows under the supply agreement, with products being sold to the partner at a pre-agreed price.
In September 2025, MaaT Pharma has been awarded the Innovative Company label ("Entreprise Innovante") by Bpifrance.
Cash position1

As of September 30, 2025, total cash and cash equivalents were EUR 22.4 million, as compared to EUR 15.0 million as of June 30, 2025, and EUR 20.2 million as of December 31, 2024.
The Company believes it has sufficient cash to cover its current operating needs and development programs until the end of February 2026.
Revenues in Q3 20251

MaaT Pharma reported revenues from France from its Early Access Program of EUR 1.0 million for the quarter ended September 30, 2025, a 56% increase over the third quarter of 2024. Total revenues for the first nine months of 2025 amounted to EUR 3.4 million compared with EUR 2.3 million for the same period of 2024, a year-over-year increase of 45%1, reflecting the continued demand from the medical community for MaaT Pharma’s drug candidate Xervyteg(MaaT013).
Upcoming financial communication*

March 30th, 2026 – Q4 and Full year 2025 financial results
*Indicative calendar that may be subject to change.

Upcoming investor and medical conferences participation

November 5-9, 2025 – 40th Society of Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) annual meeting in National Harbor, MD, USA
November 19-21, 2025 – Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) annual meeting in Geneva, Switzerland
November 25, 2025 – Investir Day event in Paris, France
December 6-9, 2025 – 67th American Society of Hematology (ASH) (Free ASH Whitepaper) annual meeting in Orlando, Fl, USA

(Press release, MaaT Pharma, NOV 4, 2025, View Source [SID1234659404])

On November 4, 2025 Agendia, Inc., a leader in precision oncology for breast cancer, reported it will present new results from the ongoing real-world FLEX Study (NCT03053193) at the 2025 San Antonio Breast Cancer Symposium (SABCS), taking place December 9-12 in San Antonio, Texas.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company will present five posters, led by Agendia investigators and independent academic collaborators, that collectively highlight the broad clinical impact of MammaPrint + BluePrint genomic profiling in optimizing treatment decisions and improving outcomes for patients with hormone receptor positive, HER2-negative (HR+/HER2–) early breast cancer (EBC).

"We look forward to sharing these new findings from the FLEX Study, which spans more than 20,000 participants across 100 global sites, making it the largest and most diverse real-world evidence cohort for early-stage breast cancer," said William Audeh, M.D., Chief Medical Officer at Agendia. "These results underscore our commitment to generating robust clinical evidence in settings beyond traditional clinical trials, ensuring the results can inform personalized treatment decisions across diverse patient populations and everyday clinical practice."

The full list of abstracts & poster presentations is as follows:

3.2yr Updated Outcome Analysis of ACT-T Benefit by MammaPrint Risk Result
Improved 3-year IDFS with anthracycline-based therapy for patients with 70-gene signature High 2, Luminal B, HR+HER2– EBC
Poster #PS2-07-03 | Dec. 10, 5:00 PM – 6:30 PM | Presenter: Joyce O’Shaughnessy

MammaPrint Provides Stronger Prognostic Value Than Histologic Grade
70-gene signature high risk classification provides stronger prognostic value than histologic grade in HR+HER2– EBC
Poster # PS5-04-19 | Dec. 12, 12:30-2:00 PM | Presenter: Erin Cobain

Older Patients with Aggressive Breast Cancer May Benefit from Chemotherapy
HR+HER2– Patients Aged ≥70 with High Risk MammaPrint Benefit from Chemotherapy
Poster #PS3-08-17 | Dec. 11, 12.30 PM – 2 PM | Presenter: Reshma Mahtani

Understanding Breast Cancer in Overweight Latin American Patients
Distinct Immune and Metabolic Profiles in Latin American Breast Cancer Patients with Obesity
Poster #PS4-09-09 | Dec. 11, 5:00 PM – 6:30 PM | Presenter: Marcela Mazo Canola

30,000-Patient Study Expanding to Improve Breast Cancer Outcomes
FLEX: From Genomic Profiling to Real-World Insights in 30,000 Patients with Early-Stage Breast Cancer
Poster #PS5-09-19 | Dec. 12 12:30-2:00 PM | Presenter: Linsey P. Gold

(Press release, Agendia, NOV 4, 2025, View Source [SID1234659403])

On November 4, 2025 Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics, reported that it will have an oral and a poster presentation at the upcoming 67th Annual American Society for Hematology (ASH) (Free ASH Whitepaper) conference, taking place December 6-9, 2025, in Orlando, FL. The presentations will focus on the company’s novel, multi-functional protein degrader program and OPN-2853, a bromodomain and extra-terminal motif (BET) inhibitor currently being tested in a Phase 1 combination study with ruxolitinib in patients with advanced myelofibrosis. Presentation details are included below.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The oral presentation will feature preclinical data from Opna’s protein degrader program, which is focused on creating novel therapeutics designed to block multiple oncogenic targets – EP300, CBP, IKZF1 and IKZF3 – concurrently in the same cancer cell. The data highlights the preclinical compound’s potential for activity as a single agent in hematological malignancies such as multiple myeloma and lymphoma.

"Our protein degrader program builds on compelling preclinical data presented at ASH (Free ASH Whitepaper) in 2024 showing strong synergy when combining immunomodulatory (IMiD) drugs and OPN-6602," said Gideon Bollag, PhD, chief scientific officer of Opna Bio. "OPN-6602, an oral, small molecule EP300/CBP inhibitor, is currently being tested in a Phase 1 study in patients with relapsed or refractory multiple myeloma at multiple sites in the U.S."

The poster presentation will highlight updated interim data from the ongoing Phase 1 study of OPN-2853 in patients with myelofibrosis who are no longer responding to ruxolitinib. This investigator-initiated study is led by Professor Adam Mead at the University of Oxford through a collaboration with Cancer Research UK (CRUK) and is run through the Cancer Research UK Clinical Trials Unit at the University of Birmingham.

ASH Presentation Details:

Title: Novel multifunctional degraders of EP300/CBP and IKZF1/3 with potent anti-myeloma activity
Publication Number: 573
Session Name: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Emerging Myeloma Disease Mechanisms and Therapeutic Strategies
Date and Session Time : December 7, 2025, 12:00 PM – 1:30 PM ET
Presentation Time: 12:30 PM – 12:45 PM ET
Presenter: Pan-Yu Chen, PhD, Associate Director, Translational Medicine, Opna Bio

Title: Interim analysis of PROMise, a clinical study combining the BET inhibitor OPN-2853 with ruxolitinib in patients with advanced myelofibrosis experiencing an inadequate response to ruxolitinib
Publication Number: 3794
Session Name: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster II
Date and Session Time: December 7, 2025, 6:00 PM – 8:00 PM ET
Presentation Time: 6:00 PM – 8:00 PM ET
Presenter: Adam Mead, PhD, Professor of Haematology, Radcliffe Department of Medicine, CRUK Senior Cancer Research Fellow

(Press release, Opna Bio, NOV 4, 2025, View Source [SID1234659402])

On November 4, 2025 Flatiron Health reported its presence at the 67th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition happening from December 6-9, 2025, in Orlando, Florida. Flatiron’s real-world data and research capabilities are featured across multiple presentations, including 12 research acceptances spanning hematologic malignancies—from CAR T cell therapy delivery and outcomes to measurable residual disease (MRD) testing patterns and treatment equity across blood cancers.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Flatiron’s presence at ASH (Free ASH Whitepaper) 2025 closely follows their announcement of six new hematology Panoramic datasets, including five B-cell lymphomas and multiple myeloma, which draw from over 505,000 relevant longitudinal patient records in Flatiron’s network. The datasets represent a six-fold increase in cohort sizes when compared to the company’s previously available datasets and lay the evidence foundation that will guide better treatment decisions, accelerate new development, and ultimately improve outcomes for patients with blood cancers.

"The rapid advancements in the treatment of hematologic malignancies have required an incredibly thoughtful approach to research, one that captures the clinical nuance of disease subtypes, rare patient cohorts, novel endpoints, and evolving biomarkers at scale," said Emily Castellanos, MD, MPH, Senior Medical Director and Head of Research Oncology at Flatiron Health. "Our presence at ASH (Free ASH Whitepaper) unlocks answers to questions that are shaping hematology care right now and our six newly launched hematology Panoramic datasets represent a clinical breakthrough, enabling researchers to study the real-world complexity of blood cancer care—from MRD testing patterns to CAR T therapy utilization—with a level of depth and rigor that was previously impossible."

Research highlights include:

Research examining real-world CAR T cell therapy delivery patterns across US oncology practices, including analysis of cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, and healthcare burden—addressing critical gaps in understanding how this transformative therapy is implemented across care settings.
Multiple studies evaluating measurable residual disease testing patterns and their association with clinical outcomes in Philadelphia-negative B-cell acute lymphoblastic leukemia and multiple myeloma, providing insights into the real-world impact of this precision monitoring approach.
EHR-derived datasets from Germany and the United Kingdom providing comprehensive analysis of diffuse large B-cell lymphoma and multiple myeloma management, demonstrating Flatiron’s ability to generate high-quality, multinational real-world evidence.
Join Flatiron Health at booth # Follow Flatiron Health on X and LinkedIn for more updates from #ASH25.

Abstracts and Poster Presentations

Use and Outcomes Following Blinatumomab Rechallenge in Adolescents and Young Adults (AYA) and Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Michaela Liedtke, Nikesh N. Shah, Jessica T. Leonard, Anthony Proli, Yazan K. Barqawi, Hui-Han Chen, Alan Yong, Vikram Shetty, Elias Jabbour, Mark B. Geyer
Author Affiliations: Stanford Cancer Institute, Tampa General Hospital Cancer Institute, Knight Cancer Institute, AstraZeneca, MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Flatiron Health
Session Name: 612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster I
Publication Number: 1555
Poster Session Date/Time: December 6, 2025, 5:30 PM – 7:30 PM

What Remains Matters: Real-World Impact of Measurable Residual Disease Testing in Multiple Myeloma
Ahmed Sawas, Farhad Khan, Jingru Wang, Evan Vietorisz, Yulia Kuznetsova, Amy Pierre, Siobhan Halloran
Session Name: 907. Outcomes Research: Plasma Cell Disorders: Poster I
Publication Number: 2789
Poster Session Date/Time: December 6, 2025, 5:30 PM – 7:30 PM

Biallelic TP53 Alterations Predict Poorer Survival in Mantle Cell Lymphoma: Insights from a National Real-World Cohort
Patrick Bliven, Xiaoyan Wang, Morgan Lael, Anosheh Afghahi, Mayur Narkhede
University of Alabama Birmingham, Flatiron Health
Session Name: 623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster I
Publication Number: 1830
Poster Session Date/Time: December 6, 2025, 5:30 PM – 7:30 PM

Mediators of Racial and Ethnic Inequities in Access to Front-Line Therapies for Chronic Lymphocytic Leukemia in the United States: A Real-World Evidence Study
Joanna M. Rhodes, Adam S. Kittai, Paul J. Hampel, Xiaoliang Wang, Qianhong Fu, Danni Zhao, Smriti Karwa, Olive Mbah, Ahmed Sawas, Benji Wagner, Rachel Myers, Derrick van Beuge, Gregory A. Maglinte, Erlene K. Seymour, Jacqueline C. Barrientos
Author Affiliations: Rutgers Cancer Institute, Icahn School of Medicine at Mount Sinai, Mayo Clinic, BeOne Medicines, Mount Sinai Comprehensive Cancer Center, Flatiron Health
Session Name: 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster I
Publication Number: 2720
Poster Session Date/Time: December 6, 2025, 5:30 PM – 7:30 PM

Real-World Insights into Diffuse Large B-Cell Lymphoma from EHR-Derived Data in Germany and the United Kingdom
Christoph Buhl, Ahmed Sawas, Arun Sujenthiran, Mohamed S Ali, Blythe Adamson
Session Name: 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster II
Publication Number: 4487
Poster Session Date/Time: December 7, 2025, 6:00 PM – 8:00 PM

Real-World Measurable Residual Disease (MRD) Testing Patterns and Associated Outcomes in Patients with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia
Anthony Proli, Jason Sharpe, Jingru Wang, Jenna Collins, Ahmed Sawas
Session Name: 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster II
Publication Number: 4484
Poster Session Date/Time: December 7, 2025, 6:00 PM – 8:00 PM

Real-World Treatment Patterns and Survival Outcomes in Second and Third Line Settings in Large B-Cell Lymphoma (LBCL)
Joseph P. McGuirk, Miguel-Angel Perales, Mark R. Fesen, Jeremy Snider, Matt Bye, Anthony J. Proli, Blythe Adamson, Samuel Hong, Babatunde Adedokun, Hil Hsu
Session Name: 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster II
Publication Number: 4503
Poster Session Date/Time: December 7, 2025, 6:00 PM – 8:00 PM

Real-World Treatment Patterns and Clinical Outcomes in High-Risk Mantle Cell Lymphoma: A Retrospective Analysis
Preetesh Jain, Anna Teschemaker, Essam Ibrahim, Taavy Miller, Danni Zhao, Ayush Kris, Ahmed Sawas, Debbie Adkins, Anouchka Chelles, Victoria Otero, Tycel Phillips
Author Affiliations: The University of Texas MD Anderson Cancer Center, AstraZeneca, City of Hope Comprehensive Cancer Center, Flatiron Health
Session Name: 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster II
Publication Number: 4482
Poster Session Date/Time: December 7, 2025, 6:00 PM – 8:00 PM

Beyond the Trial: Real-World CRS, ICANS, and Healthcare Burden of CAR T-Cell Therapy Across US Oncology Practices
Taiga Nishihori, Li Chen, Benjamin Wagner, Niquelle Wadé, Selina Radlein, Spencer Langerman, Trong Le, Ahmed Sawas, Christina Fullerton
Author Affiliations: Moffitt Cancer Center, Flatiron Health
Session Name: 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster III
Publication Number: 6263
Poster Session Date/Time: December 8, 2025, 6:00 PM – 8:00 PM

Barriers and Bridges: Real-World CAR T Delivery Across US Oncology Practices
Taiga Nishihori, Maneet Kaur, Spencer Langerman, Christina Fullerton, Ahmed Sawas
Author Affiliations: Moffitt Cancer Center, Flatiron Health
Session Name: 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster III
Publication Number: 6262
Poster Session Date/Time: December 8, 2025, 6:00 PM – 8:00 PM

Real-World Insights into Multiple Myeloma Management: An Analysis of EHR-Derived Data in the UK and Germany
Christoph Buhl, Harlan Pittell, Arun Sujenthiran, Ahmed Sawas, Golnessa Mojtahedi, Blythe Adamson
Online only

The Bispecific Blind Spot: Uncovering Real-World Inequities in Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Multiple Myeloma Therapy Access
Gene G. Ho, Olive M. Mbah, Cleo A. Ryals, Amy E. Pierre
Online only

(Press release, Flatiron Health, NOV 4, 2025, View Source [SID1234659401])